The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Disease Areas
Mini-Oral
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
A DESTINY-Breast09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs)
Cristina Saura
View presentation
Oral
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Breast Cancer
A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P)
Yeon Hee Park
View presentation
Poster
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy followed by palbociclib, endocrine therapy (ET), and dual HER2 blockade in first-line (1L) human epidermal growth factor receptor 2–positive (HER2+), hormone receptor–positive (HR+) advanced or metastatic breast cancer (mBC) and retreatment with T-DXd (DESTINY-Breast Guide)
Sarah Sammons
View presentation
Oral
T-DXd
JSMO 2026 | March 26-28, 2026
Breast Cancer
A health-related quality-of-life analysis from ERICA study (WJOG14320B)
Hitomi Sakai
View presentation
Poster
T-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
A multicenter, retrospective study to determine the prevalence of HER2-low & associated outcomes in patients previously identified with HER2 negative locally advanced (LA) or metastatic breast cancer (mBC) who progressed on systemic anticancer therapy: Interim analysis of iRetroBC-HER2L study
Senthil Rajappa
View presentation
Mini-Oral
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
Additional efficacy and safety from the DESTINY-Breast05 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary early breast cancer with residual invasive disease after neoadjuvant therapy
Sibylle Loibl
View presentation
Oral
T-DXd
JBCS 2025 | July 10-12, 2025
Breast Cancer
AI-based analyses of trastuzumab deruxtecan-related interstitial lung disease/pneumonitis: TILD-A
Naoya Tanabe
View presentation
Mini-Oral
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
CHARISMA: Paired-biopsy multi-omic CHAacterization reveals targetindependent ResIStance Mechanisms to Antibody-drug conjugates
Paolo Tarantino
View presentation
Poster
T-DXd
ESMO 2026 | October 23 - 27, 2026
Breast Cancer
Comparative evaluation of 7 artificial intelligence (AI) tools for HER2-low and ultralow scoring in breast cancer
Jean-Sébastien Frenel
View presentation
Poster
T-DXd
AACR 2026 | April 17-22, 2026
Breast Cancer
Comparison of digital and computational algorithms for quantifying human epidermal growth factor receptor 2 (HER2) protein expression in metastatic breast cancer (mBC) from clinical samples
Savitri Krishnamurthy
View presentation
Pages: 1  2  3  4  5  6  7  8  9  
Connect with an MSL
Linkedin Icon Twitter Icon

©2026  Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24